Non-exclusive agreements for medicinal products containing Roxadustat (ATC B03XA05) via an open-house model
Original notice title
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Roxadustat (ATC-Code: B03XA05) im Wege eines Open-House-Modells
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No guaranteed volumes; actual demand depends on patient numbers, prescribing behavior, and pharmacy stocking.
The agreement may be terminated early if the buyer concludes exclusive agreements, typically 8-12 months after publicat...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- May 31, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2028
- Non-exclusive supply of medicinal products containing Roxadustat (ATC B03XA05)
- Open-house model allowing any qualified pharmaceutical company to participate
Show full summary
This notice announces a non-exclusive open-house model agreement for pharmaceutical products containing Roxadustat (ATC B03XA05), organized by AOK PLUS for the regions of Saxony and Thuringia, Germany. The agreement has no guaranteed volumes, no exclusivity, and allows any qualified pharmaceutical company to join during the participation period. The procedure is not a public procurement under EU directives but a voluntary transparency measure. Submissions are accepted periodically until 31 May 2028, with the first deadline on 30 April 2026.
Risks
No guaranteed volumes; actual demand depends on patient numbers, prescribing behavior, and pharmacy stocking.
The agreement may be terminated early if the buyer concludes exclusive agreements, typically 8-12 months after publicat...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company as defined in §4(18) AMG
- Must have a registered office within the EU/EEA or Germany
- Must accept the non-exclusive, no-negotiation open-house model
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive agreements for medicinal products containing Roxadustat (ATC B03XA05) via an open-house model
Non-exclusive framework agreement for the supply of Roxadustat (ATC B03XA05) under an open-house model. No minimum purchase quantities, no exclusivity, and individual negotiations are not conducted. The agreement ends no later than 31 May 2028.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Roxadustat (ATC-Code: B03XA05) im Wege eines Open-House-Modells
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 29 Mar 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 216077-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No guaranteed volumes; actual demand depends on patient numbers, prescribing behavior, and pharmacy stocking.
The agreement may be terminated early if the buyer concludes exclusive agreements, typically 8-12 months after publicat...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications